Latest Biotech News

The FDA approved AbbVie’s next-generation dopamine therapy for Parkinson’s disease, tavapadon, which will be marketed as Juvmo. The approval reflects the agency’s view that the compound can...

An oral Wnt-pathway blocking candidate combined with lenvatinib showed durable tumor shrinkage in women with advanced endometrial cancer after immunotherapy failed. The results, published in...

Researchers identified a molecular “fission protein” switch, MFF, that senses and drives ferroptosis in a Nature study. Ferroptosis is the iron-dependent cell death program implicated across...

A large investigation found that hidden blood pressure drops are common after cellular therapies, with most patients experiencing orthostatic hypotension within the first month of treatment. The...

New mechanistic data suggest OM-89, long used to help prevent recurrent UTIs, protects by acting directly on bladder epithelial cells rather than only via immune stimulation. Research published in...

A machine-learning approach reportedly rescued “impossible” human drug transporter mutations on an in-silico basis, highlighting how computational tools can expand the set of viable transporter...

A simple blood marker may help predict five-year survival in older adults, according to a study centered on red cell distribution width (RDW). RDW is derived from routine complete blood counts and...

The FDA approved Mirum Pharmaceuticals’ zilurgisertib (Atebrioz), the third treatment for an ultra-rare genetic disorder that causes muscle and connective tissue to turn into bone. Zilurgisertib...

ADARx Pharmaceuticals made its trading debut after a $535M public listing, supported by an upsized IPO and additional cash from a private placement with partner AbbVie. The company’s lead program,...

Researchers reported that RNA splicing errors in transporter genes may predict cancer survival across 33 tumor types, linking transcript processing defects to clinical outcomes. The study, led by...

The FDA approved AbbVie’s next-generation dopamine therapy for Parkinson’s disease, tavapadon, which will be marketed as Juvmo. The dopamine agonist is positioned as a successor to existing...

In extensive-stage small cell lung cancer, Ifinatamab deruxtecan’s BLA was voluntarily withdrawn for previously treated patients. The move signals an early retreat from development in that...

ADARx Pharmaceuticals’ IPO debuted with heavy retail and institutional demand, following an upsized offering and a private placement supported by partner AbbVie. The gene-silencing biotech priced...

A jury awarded Nektar Therapeutics $90 million in its dispute with Eli Lilly over the development of rezpeg, a Treg stimulator. The verdict found Lilly breached the implied covenant of good faith...

Remynd NV raised €3.5 million from the Alzheimer’s Drug Discovery Foundation to advance REM-392, an orally available septin-targeting small molecule. The company said the additional funding...

Novo Nordisk struck a technology licensing deal worth up to €1.165 billion for global exclusive rights to Nanexa AB’s drug delivery platform. The transaction is designed to support Novo’s broader...

A comprehensive review maps how CAR-T cell therapy has moved beyond blood cancers, documenting approvals and new indications while also summarizing where solid tumor and autoimmune attempts are...

A large investigation found that more than half of patients receiving cellular therapies experience orthostatic hypotension, with most cases occurring within the first month. The study describes...

Sanofi’s regulatory CMC head, Manda Pasarkar, outlined how ICH’s first major revision to the M4Q quality module in more than 20 years could reshape marketing applications. The shift to M4Q(R2) is...

Pharmaceutical industry groups asked the FDA for more clarity on when a single pivotal trial plus confirmatory evidence is sufficient for approval. The push reflects ongoing uncertainty in how...